These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27236131)

  • 1. Iron Treatment Strategies in Dialysis-Dependent CKD.
    Pandey R; Daloul R; Coyne DW
    Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
    Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron Treatment Strategies in Nondialysis CKD.
    Macdougall IC
    Semin Nephrol; 2016 Mar; 36(2):99-104. PubMed ID: 27236130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Potthoff SA; Münch HG
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
    BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia.
    Dalimunthe NN; Lubis AR
    Rom J Intern Med; 2016; 54(1):31-6. PubMed ID: 27141568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Iron supplementation in chronic kidney disease].
    Graczyk M; Dylewska M
    Wiad Lek; 2017; 70(6 pt 2):1215-1218. PubMed ID: 29533917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
    Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
    Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron Deficiency in Heart Failure: An Overview.
    von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD
    JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
    Folkert VW
    Nephrol Nurs J; 2003 Oct; 30(5):571-6, 584. PubMed ID: 14621635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
    Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
    Takasawa K; Takaeda C; Wada T; Ueda N
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
    [No Abstract]   [Full Text] [Related]  

  • 19. A study of parenteral iron regimens in hemodialysis patients.
    Besarab A; Kaiser JW; Frinak S
    Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.